



## **Zymeworks Inc. selected as a finalist for British Columbia Technology Industry Association's Technology Impact Award**

**Vancouver, Canada, May 12, 2008** – Zymeworks Inc. is pleased to announce that it has been selected as a finalist for British Columbia Technology Industry Association's (BCTIA) Technology Impact Awards, in the category of Most Promising Pre-Commercial Technology. The award will be presented at the Technology Impact Awards Celebration at the Hyatt Regency Vancouver on June 12, 2008.

### **About Zymeworks Inc.**

Zymeworks is a computational biotechnology company that combines proprietary molecular simulation technology with high performance computing to research and develop industrial enzymes and protein therapeutics. Zymeworks uses its proprietary ZymeCAD™ molecular simulation platform and world-class team of protein engineers to alter enzyme substrate specificity and antibody-binding affinities. The ZymeCAD™ suite of applications creates a highly detailed computational modeling environment for accurate and predictive semi-rational protein engineering. This detailed physical and chemical insight is used to address the specific needs of Zymeworks' customers and advance its protein-therapeutics pipeline.

### **About BCTIA's Technology Impact Award – Most Promising Pre-Commercial Technology**

BCTIA's Technology Impact Award – Most Promising Pre-Commercial Technology recognizes a pre-commercial technology in the R&D stage of development with the potential to commercialize within five years and represents a fundamental advancement in technology. Past Winner: Nutri-Loc (2007)

For further information, contact Dr. David Poon, Business Development Associate at:

Tel: 604-678-1388

E-mail: [info@zymeworks.com](mailto:info@zymeworks.com)

Website: [www.zymeworks.com](http://www.zymeworks.com)